Wednesday, December 02, 2020 3:31:34 PM
The well is running low, major PPS spikes coming on any major news.
https://ih.advfn.com/stock-market/NASDAQ/biocryst-pharmaceuticals-BCRX/stock-news/83805940/biocryst-reports-inducement-grants-under-nasdaq-li
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 13 newly-hired employees inducement options to purchase an aggregate of 260,500 shares of BioCryst common stock on November 30, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $5.11 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.
Recent BCRX News
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/03/2024 11:00:07 AM
- BioCryst to Report First Quarter 2024 Financial Results on May 6 • GlobeNewswire Inc. • 04/22/2024 11:00:50 AM
- BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency • GlobeNewswire Inc. • 04/17/2024 08:30:39 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/03/2024 11:00:23 AM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 03/25/2024 08:01:00 PM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/05/2024 12:01:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:25:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:32:01 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/27/2024 10:05:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:05:56 PM
- BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones • GlobeNewswire Inc. • 02/26/2024 12:00:05 PM
- U.S. Index Futures Dip Amid Inflation Data Anticipation, Oil and Iron Ore Prices Retreat • IH Market News • 02/26/2024 10:57:28 AM
- BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment • GlobeNewswire Inc. • 02/23/2024 12:00:00 PM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/21/2024 09:01:58 PM
- BioCryst Launches ORLADEYO® (berotralstat) in Italy • GlobeNewswire Inc. • 02/19/2024 12:54:52 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:21:51 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 02:02:50 PM
- BioCryst to Report Fourth Quarter 2023 Financial Results on February 26 • GlobeNewswire Inc. • 02/12/2024 12:00:53 PM
- BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting • GlobeNewswire Inc. • 02/05/2024 12:00:00 PM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/02/2024 12:00:48 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/24/2024 10:23:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 10:21:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:02:39 PM
- BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability • GlobeNewswire Inc. • 01/05/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:31:49 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM